Summary
In a companion paper we described the disposition of a 75 mg single dose of amitriptyline in normal volunteers who were phenotyped as extensive or poor metabolizers of debrisoquine and bufuralol, and had a four-fold range in the oral clearance of the antidepressant, 50 mg of amitriptyline was also administered to the same volunteers. This paper compares the results after both doses and suggests that the disposition of amitriptyline is linear even in subjects with a low oral clearance. There was no relation between the pharmacokinetic data and the intensity of sedation or of psychomotor impairment.
Similar content being viewed by others
References
Balant-Gorgia AE, Schulz P, Dayer P, Balant L, Kubli A, Gertsch-Genet C, Garrone G (1982) Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 232:215–222
Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Balant-Gorgia AE, Fabre J (1982) The genetic control of bufuralol in man. Eur J Drug Metab Pharmacokin 7:33–77
Hyttel J, Christensen AV, Fjalland B (1980) Neuropharmacological properties of amitriptyline, nortriptyline and their metabolites. Acta Pharmacol et Toxicol 47: 53–57
Madakasira S, Preskorn S, Weller R, Pardo M (1982) Single dose prediction of steady state plasma levels of amitriptyline. J Clin Psychopharmacol 2:137–139
Schulz P, Walser A, Meyer JJ, Kubli A, Garrone G (1983) Traduction française de la Stanford Sleepiness Scale (SSS) et utilisation de cette échelle de sédation après dose unique de midazolam ou d'amitriptyline. Agressologie (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schulz, P., Balant-Gorgia, A.E., Kubli, A. et al. Elimination and pharmacological effects following single oral doses of 50 and 75 mg of amitriptyline in man. Arch Psychiatr Nervenkr 233, 449–455 (1983). https://doi.org/10.1007/BF00342785
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00342785